A National Institute for Health and Care Excellence (NICE) – NICE recommends lisocabtagene maraleucel for treating people with large B-cell lymphoma
NICE has released its final guidance recommending Breyanzi (also known as lisocabtagene maraleucel or liso-cel) as a treatment option for individuals with large B-cell lymphoma whose cancer has either not responded to initial treatment or relapsed within 12 months. This positive recommendation marks a reversal from an initial negative draft recommendation in October 2024 following an improved commercial arrangement offered by Bristol Myers Squibb to the NHS. Breyanzi, an innovative one-time cell therapy, is now accessible through routine commissioning. Please find further information here.
News reported on the 2nd of April 2025 in Catapult’s regulatory round-up, read the entire report here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 mai 2025). A National Institute for Health and Care Excellence (NICE) – NICE recommends lisocabtagene maraleucel for treating people with large B-cell lymphoma . ELSIBI. Consulté le 13 janvier 2026 à l’adresse https://doi.org/10.58079/13yf8





